Breaking News

Sionna Licenses Abbvie Assets to Advance Cystic Fibrosis Treatments

Exclusive rights to two Phase 2 compounds and a Phase 1 compound expand Sionna’s pipeline of modulators to combine with its NBD1 stabilizers.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Sionna Therapeutics, a clinical-stage life sciences company developing differentiated treatments for cystic fibrosis (CF), has obtained exclusive worldwide rights to develop and commercialize multiple clinical-stage compounds through a license agreement with AbbVie.  Under the agreement, Sionna will assume all development responsibilities for galicaftor (ABBV-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) corrector, and navocaftor (...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters